Moderna Gains FDA Approval for MFLUSIVA, First mRNA Influenza Vaccine Cleared in the US

The FDA's clearance of Moderna's MFLUSIVA (BLA 125869/0) on August 5, 2026 marks the first mRNA-platform influenza vaccine to clear the agency's biologics licensing pathway, a development that reshapes the manufacturing and regulatory calculus for every biologics facility currently producing or planning seasonal flu vaccine.

MFLUSIVA is indicated for active immunization against influenza virus subtypes A and type B strains represented in the vaccine, approved for use in persons 50 years of age and older. The approval was issued under the standard BLA route, confirming that mRNA-based influenza candidates can satisfy existing biologics evidentiary requirements without a novel regulatory framework.

For QA directors and plant heads operating egg-based or cell-culture influenza lines, the competitive pressure is now structural. Moderna's mRNA platform offers a strain-update cycle that is materially faster than traditional manufacturing methods, a factor that has direct implications for capacity planning, batch release timelines, and annual reformulation readiness. Facilities evaluating platform diversification will need to weigh capital investment in lipid nanoparticle manufacturing infrastructure against the regulatory precedent this BLA now establishes.

Regulatory affairs leads preparing BLA submissions for mRNA vaccine candidates gain a concrete reference point. The approved package insert and supporting documentation, including the August 5 approval letter, are publicly available via the FDA vaccines and biologics portal, providing a navigable precedent for 21 CFR Part 601 filing strategy, labeling conventions, and post-approval commitment structures for mRNA biologics.

The approval also signals that FDA reviewers have developed sufficient familiarity with mRNA-specific analytical methods, stability data packages, and potency assay frameworks to adjudicate a full BLA in the influenza space, a signal relevant to sponsors advancing mRNA candidates in adjacent infectious disease indications.

The first commercial season under this approval will serve as the operational benchmark: strain selection timelines, lot release throughput, and pharmacovigilance data generated in the 50-and-older population will define the evidentiary baseline regulators and competitors reference going forward.

Source: FDA Vaccines, Blood and Biologics via What's New RSS Feed, August 6, 2026.